Literature DB >> 25860392

Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009.

E F Duffell1, M J van de Laar.   

Abstract

Hepatitis B and C viral infections are leading causes of hepatic cirrhosis and cancer. The incidence and prevalence of both hepatitis B and C varies across European countries. European wide surveillance data help to understand the dynamic epidemiology of hepatitis B and C, which is important for the implementation and effectiveness of prevention and control activities.Comparison of surveillance data between countries in Europe is hampered by the differences in national healthcare and reporting systems. This report presents the results of a survey in 2009 which was undertaken to collect baseline information on surveillance systems and core prevention programmes for hepatitis B and C in individual European Union/ European Economic Area countries. The results provide key information to aid the interpretation of surveillance data, and while indicating heterogeneity in national surveillance systems and programmes, they highlight the potential of these systems. This resource has supported the implementation of a standardised European enhanced surveillance programme.

Entities:  

Mesh:

Year:  2015        PMID: 25860392     DOI: 10.2807/1560-7917.es2015.20.13.21080

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  6 in total

1.  Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China.

Authors:  Shigui Yang; Chengbo Yu; Ping Chen; Min Deng; Qing Cao; Yiping Li; Jingjing Ren; Kaijin Xu; Jun Yao; Tiansheng Xie; Chencheng Wang; Yuanxia Cui; Cheng Ding; Guo Tian; Bing Wang; Xiaoyan Zhang; Bing Ruan; Lanjuan Li
Journal:  Sci Rep       Date:  2015-12-14       Impact factor: 4.379

2.  Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions.

Authors:  Erika F Duffell; Dagmar Hedrich; Otilia Mardh; Antons Mozalevskis
Journal:  Euro Surveill       Date:  2017-03-02

3.  Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014.

Authors:  Alessandro Miglietta; Chantal Quinten; Pier Luigi Lopalco; Erika Duffell
Journal:  Euro Surveill       Date:  2018-02

4.  Hepatitis B virus S gene therapy with 10-23 DNAzyme delivered by chitosan-g-stearic acid micelles.

Authors:  Yun Hong; Dongsen Mao; Rui Wu; Zhe Gao; Tingting Meng; Rongrong Wang; Lin Liu; Jing Miao
Journal:  RSC Adv       Date:  2019-05-15       Impact factor: 4.036

5.  Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014.

Authors:  Prabhu P Gounder; Anders Koch; Ginger Provo; Astrid Lovlie; Josefine Lundberg Ederth; Maria Axelsson; Chris P Archibald; Brendan Hanley; Angie Mullen; Myrna Matheson; David Allison; Henrik Trykker; Thomas W Hennessy; Markku Kuusi; Vladimir Chulanov; Brian J McMahon
Journal:  Euro Surveill       Date:  2018-10

Review 6.  A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals.

Authors:  Laura Ambra Nicolini; Andrea Orsi; Paola Tatarelli; Claudio Viscoli; Giancarlo Icardi; Laura Sticchi
Journal:  Int J Environ Res Public Health       Date:  2019-09-09       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.